



Emergent BioSolutions to Participate in Investor Conferences

January 4, 2021

GAITHERSBURG, Md., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's executive management team will participate in the following investor conferences in the first quarter of 2021:

- **39th Annual J.P. Morgan Healthcare Conference**
January 11 to 14, 2021
Company presentation scheduled on January 11 at 8:20am EST
- **J.P. Morgan 2021 Global High Yield & Leveraged Finance Conference**
March 1 to 3, 2021
Presentation date and time will be updated on the Emergent website as the information becomes available.
- **Cowen 41st Annual Health Care Conference**
March 1 to 4, 2021
Presentation date and time will be updated on the Emergent website as the information becomes available.

For conferences where a presentation is planned, the company's webcast presentation may include a discussion of the company's recent business developments as well as its financial results and guidance. The webcasts will be available both live, if possible, and by replay, and will be accessible from the [Emergent website](#).

About Emergent BioSolutions

Emergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through our specialty products and contract development and manufacturing services, we are dedicated to providing solutions that address public health threats. Through social responsibility, we aim to build healthier and safer communities. We aspire to deliver peace of mind to our patients and customers so they can focus on what's most important in their lives. In working together, we envision protecting or enhancing 1 billion lives by 2030. For more information, visit our [website](#) and follow us on [LinkedIn](#), [Twitter](#), and [Instagram](#).

Investor Contact:

Robert G. Burrows
Vice President, Investor Relations
240-631-3280
burrowsr@ebsi.com

Media Contact:

Miko B. Neri
Senior Director, Global Communications & Public Affairs
240-631-3392
nerim@ebsi.com



Source: Emergent BioSolutions